{"title_page": "AM404", "text_new": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 477236071\n| IUPAC_name = (5''Z'',8''Z'',11''Z'',14''Z'')- ''N''-(4-Hydroxyphenyl)icosa- 5,8,11,14-tetraenamide\n| image = AM404_skel.svg\n| width = 240\n<!--Clinical data-->\n| tradename =  \n| legal_status =  \n| routes_of_administration =\n<!--Pharmacokinetic data-->\n| elimination_half-life =  \n| excretion =\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 183718-77-6\n| CAS_supplemental = {{CAS|198022-70-7}}\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = XVJ94H0U21\n| PubChem = 6604822\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| ChemSpiderID = 5037081\n| ChEMBL_Ref = {{ebicite|correct|EBI}}\n| ChEMBL = 39878\n<!--Chemical data-->\n| C=26 | H=37 | N=1 | O=2\n| molecular_weight = 395.577 g/mol\n| smiles = O=C(Nc1ccc(O)cc1)CCC\\C=C/C\\C=C/C\\C=C/C\\C=C/CCCCC\n| StdInChI_Ref = {{stdinchicite|correct|chemspider}}\n| StdInChI = 1S/C26H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26(29)27-24-20-22-25(28)23-21-24/h6-7,9-10,12-13,15-16,20-23,28H,2-5,8,11,14,17-19H2,1H3,(H,27,29)/b7-6-,10-9-,13-12-,16-15-\n| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}\n| StdInChIKey = IJBZOOZRAXHERC-DOFZRALJSA-N\n}}\n'''AM404''', also known as '''''N''-arachidonoylaminophenol''',<ref name=\"pmid22172309\">{{cite journal |vauthors=Rogosch T, Sinning C, Podlewski A, Watzer B, Schlosburg J, Lichtman AH, Cascio MG, Bisogno T, Di Marzo V, N\u00fcsing R, Imming P | title = Novel bioactive metabolites of dipyrone (metamizol) | journal = Bioorg. Med. Chem. | volume = 20 | issue = 1 | pages = 101\u20137 |date=January 2012 | pmid = 22172309 | pmc = 3248997 | doi = 10.1016/j.bmc.2011.11.028 }}</ref> is an [[active metabolite]] of [[paracetamol]] (acetaminophen), responsible for all or part of its [[analgesic]] action<ref name=\"pmid16438952\">{{cite journal |vauthors=Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A | title = The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors | journal = Eur. J. Pharmacol. | volume = 531 | issue = 1\u20133 | pages = 280\u20131 |date=February 2006 | pmid = 16438952 | doi = 10.1016/j.ejphar.2005.12.015 }}</ref> and [[anticonvulsant]] effects.<ref name=\":0\">{{Cite journal|last=Deshpande|first=Laxmikant S.|last2=DeLorenzo|first2=Robert J.|date=2011-01-05|title=Acetaminophen inhibits status epilepticus in cultured hippocampal neurons|journal=NeuroReport|volume=22|issue=1|pages=15\u201318|doi=10.1097/WNR.0b013e3283413231|issn=0959-4965|pmc=3052417|pmid=21037491}}</ref> Chemically, it is the [[amide]] formed from [[4-Aminophenol|4-aminophenol]] and [[arachidonic acid]].\n\n== Pharmacology ==\n\nAM404 was originally reported to be an [[endocannabinoid reuptake inhibitor|endogenous cannabinoid reuptake inhibitor]], preventing the transport of [[anandamide]] and other related compounds back from the [[synapse|synaptic cleft]], much in the same way that common [[selective serotonin reuptake inhibitor]] (SSRI) antidepressants prevent the reuptake of [[serotonin]]. Earlier work on the mechanism of AM404 suggested that the inhibition of [[fatty acid amide hydrolase]] (FAAH) by AM404 was responsible for all of its attributed reuptake properties, since intracellular FAAH hydrolysis of [[anandamide]] changes the intra/extracellular anandamide equilibrium.<ref name=\"pmid12655057\">{{cite journal |vauthors=Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG | title = Evidence against the presence of an anandamide transporter | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 100 | issue = 7 | pages = 4269\u201374 |date=April 2003 | pmid = 12655057 | pmc = 153082 | doi = 10.1073/pnas.0730816100 }}</ref> However, this is not the case, as newer research on FAAH knockout mice has found that brain cells internalize anandamide through a selective transport mechanism which is independent of FAAH activity.<ref>{{cite journal|last=Fegley|first=D.|author2=Kathuria, S.|author3=Mercier, R.|author4=Li, C.|author5=Goutopoulos, A.|author6=Makriyannis, A.|authorlink6=Alexandros Makriyannis|author7= Piomelli, D.|title=Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172|journal=Proceedings of the National Academy of Sciences|date=11 May 2004|volume=101|issue=23|pages=8756\u20138761|doi=10.1073/pnas.0400997101|pmid=15138300|pmc=423268}}</ref> This mechanism is inhibited by AM404.\n\nAM404 is also a [[TRPV1]] agonist and inhibitor of [[cyclooxygenase]] COX-1 and COX-2, thus attenuating [[prostaglandin]] synthesis. AM404 is thought to induce its analgesic action through its activity on the [[endocannabinoid system|endocannabinoid]], [[COX]], and [[TRPV]] systems, all of which are present in [[Nociception|pain]] and [[thermoregulation|thermoregulatory]] pathways.<ref name=\"pmid15987694\">{{cite journal |vauthors=H\u00f6gest\u00e4tt ED, J\u00f6nsson BA, Ermund A, Andersson DA, Bj\u00f6rk H, Alexander JP, Cravatt BF, Basbaum AI, Zygmunt PM | title = Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system | journal = J. Biol. Chem. | volume = 280 | issue = 36 | pages = 31405\u201312 |date=September 2005 | pmid = 15987694 | doi = 10.1074/jbc.M501489200 | url = http://www.jbc.org/content/280/36/31405.full.pdf | format = pdf }}</ref> AM404 activates [[vanilloid receptor]]s causing [[vasodilation]] which is inhibited by the vanilloid receptor antagonist capsazepine.<ref>{{Cite journal|last=Zygmunt|first=P. M.|last2=Chuang|first2=H.|last3=Movahed|first3=P.|last4=Julius|first4=D.|last5=H\u00f6gest\u00e4tt|first5=E. D.|date=2000-05-12|title=The anandamide transport inhibitor AM404 activates vanilloid receptors|journal=European Journal of Pharmacology|volume=396|issue=1|pages=39\u201342|issn=0014-2999|pmid=10822052|doi=10.1016/s0014-2999(00)00207-7}}</ref>\n\nThe anticonvulsant action is mediated through [[Cannabinoid receptor type 1|CB1 receptors]].<ref name=\":0\" />\n\n==See also==\n* [[VDM-11]] (2-methyl analogue)\n\n== References ==\n{{Reflist}}\n\n{{Cannabinoids}}\n{{Analgesics}}\n{{Cannabinoid receptor modulators}}\n{{Prostanoid signaling modulators}}\n{{Transient receptor potential channel modulators}}\n\n\n[[Category:Anilides]]\n[[Category:Phenols]]\n[[Category:AM cannabinoids]]\n[[Category:Fatty acid amides]]\n[[Category:Human drug metabolites]]\n[[Category:Endocannabinoid reuptake inhibitors]]\n", "text_old": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 477236071\n| IUPAC_name = (5''Z'',8''Z'',11''Z'',14''Z'')- ''N''-(4-Hydroxyphenyl)icosa- 5,8,11,14-tetraenamide\n| image = AM404_skel.svg\n| width = 240\n<!--Clinical data-->\n| tradename =  \n| legal_status =  \n| routes_of_administration =\n<!--Pharmacokinetic data-->\n| elimination_half-life =  \n| excretion =\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 183718-77-6\n| CAS_supplemental = {{CAS|198022-70-7}}\n| PubChem = 6604822\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| ChemSpiderID = 5037081\n| ChEMBL_Ref = {{ebicite|correct|EBI}}\n| ChEMBL = 39878\n<!--Chemical data-->\n| C=26 | H=37 | N=1 | O=2\n| molecular_weight = 395.577 g/mol\n| smiles = O=C(Nc1ccc(O)cc1)CCC\\C=C/C\\C=C/C\\C=C/C\\C=C/CCCCC\n| StdInChI_Ref = {{stdinchicite|correct|chemspider}}\n| StdInChI = 1S/C26H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26(29)27-24-20-22-25(28)23-21-24/h6-7,9-10,12-13,15-16,20-23,28H,2-5,8,11,14,17-19H2,1H3,(H,27,29)/b7-6-,10-9-,13-12-,16-15-\n| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}\n| StdInChIKey = IJBZOOZRAXHERC-DOFZRALJSA-N\n}}\n'''AM404''', also known as '''''N''-arachidonoylaminophenol''',<ref name=\"pmid22172309\">{{cite journal |vauthors=Rogosch T, Sinning C, Podlewski A, Watzer B, Schlosburg J, Lichtman AH, Cascio MG, Bisogno T, Di Marzo V, N\u00fcsing R, Imming P | title = Novel bioactive metabolites of dipyrone (metamizol) | journal = Bioorg. Med. Chem. | volume = 20 | issue = 1 | pages = 101\u20137 |date=January 2012 | pmid = 22172309 | pmc = 3248997 | doi = 10.1016/j.bmc.2011.11.028 }}</ref> is an [[active metabolite]] of [[paracetamol]] (acetaminophen), responsible for all or part of its [[analgesic]] action<ref name=\"pmid16438952\">{{cite journal |vauthors=Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A | title = The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors | journal = Eur. J. Pharmacol. | volume = 531 | issue = 1\u20133 | pages = 280\u20131 |date=February 2006 | pmid = 16438952 | doi = 10.1016/j.ejphar.2005.12.015 }}</ref> and [[anticonvulsant]] effects.<ref name=\":0\">{{Cite journal|last=Deshpande|first=Laxmikant S.|last2=DeLorenzo|first2=Robert J.|date=2011-01-05|title=Acetaminophen inhibits status epilepticus in cultured hippocampal neurons|journal=NeuroReport|volume=22|issue=1|pages=15\u201318|doi=10.1097/WNR.0b013e3283413231|issn=0959-4965|pmc=3052417|pmid=21037491}}</ref> Chemically, it is the [[amide]] formed from [[4-Aminophenol|4-aminophenol]] and [[arachidonic acid]].\n\n== Pharmacology ==\n\nAM404 was originally reported to be an [[endocannabinoid reuptake inhibitor|endogenous cannabinoid reuptake inhibitor]], preventing the transport of [[anandamide]] and other related compounds back from the [[synapse|synaptic cleft]], much in the same way that common [[selective serotonin reuptake inhibitor]] (SSRI) antidepressants prevent the reuptake of [[serotonin]]. Earlier work on the mechanism of AM404 suggested that the inhibition of [[fatty acid amide hydrolase]] (FAAH) by AM404 was responsible for all of its attributed reuptake properties, since intracellular FAAH hydrolysis of [[anandamide]] changes the intra/extracellular anandamide equilibrium.<ref name=\"pmid12655057\">{{cite journal |vauthors=Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG | title = Evidence against the presence of an anandamide transporter | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 100 | issue = 7 | pages = 4269\u201374 |date=April 2003 | pmid = 12655057 | pmc = 153082 | doi = 10.1073/pnas.0730816100 }}</ref> However, this is not the case, as newer research on FAAH knockout mice has found that brain cells internalize anandamide through a selective transport mechanism which is independent of FAAH activity.<ref>{{cite journal|last=Fegley|first=D.|author2=Kathuria, S.|author3=Mercier, R.|author4=Li, C.|author5=Goutopoulos, A.|author6=Makriyannis, A.|authorlink6=Alexandros Makriyannis|author7= Piomelli, D.|title=Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172|journal=Proceedings of the National Academy of Sciences|date=11 May 2004|volume=101|issue=23|pages=8756\u20138761|doi=10.1073/pnas.0400997101|pmid=15138300|pmc=423268}}</ref> This mechanism is inhibited by AM404.\n\nAM404 is also a [[TRPV1]] agonist and inhibitor of [[cyclooxygenase]] COX-1 and COX-2, thus attenuating [[prostaglandin]] synthesis. AM404 is thought to induce its analgesic action through its activity on the [[endocannabinoid system|endocannabinoid]], [[COX]], and [[TRPV]] systems, all of which are present in [[Nociception|pain]] and [[thermoregulation|thermoregulatory]] pathways.<ref name=\"pmid15987694\">{{cite journal |vauthors=H\u00f6gest\u00e4tt ED, J\u00f6nsson BA, Ermund A, Andersson DA, Bj\u00f6rk H, Alexander JP, Cravatt BF, Basbaum AI, Zygmunt PM | title = Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system | journal = J. Biol. Chem. | volume = 280 | issue = 36 | pages = 31405\u201312 |date=September 2005 | pmid = 15987694 | doi = 10.1074/jbc.M501489200 | url = http://www.jbc.org/content/280/36/31405.full.pdf | format = pdf }}</ref> AM404 activates [[vanilloid receptor]]s causing [[vasodilation]] which is inhibited by the vanilloid receptor antagonist capsazepine.<ref>{{Cite journal|last=Zygmunt|first=P. M.|last2=Chuang|first2=H.|last3=Movahed|first3=P.|last4=Julius|first4=D.|last5=H\u00f6gest\u00e4tt|first5=E. D.|date=2000-05-12|title=The anandamide transport inhibitor AM404 activates vanilloid receptors|journal=European Journal of Pharmacology|volume=396|issue=1|pages=39\u201342|issn=0014-2999|pmid=10822052|doi=10.1016/s0014-2999(00)00207-7}}</ref>\n\nThe anticonvulsant action is mediated through [[Cannabinoid receptor type 1|CB1 receptors]].<ref name=\":0\" />\n\n==See also==\n* [[VDM-11]] (2-methyl analogue)\n\n== References ==\n{{Reflist}}\n\n{{Cannabinoids}}\n{{Analgesics}}\n{{Cannabinoid receptor modulators}}\n{{Prostanoid signaling modulators}}\n{{Transient receptor potential channel modulators}}\n\n\n[[Category:Anilides]]\n[[Category:Phenols]]\n[[Category:AM cannabinoids]]\n[[Category:Fatty acid amides]]\n[[Category:Human drug metabolites]]\n[[Category:Endocannabinoid reuptake inhibitors]]\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/AM404"}
